NeuroMetrix (NURO) Misses Q1 EPS by 42c

NeuroMetrix (NASDAQ: NURO) reported Q1 EPS of ($0.91), $0.42 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $4.3 million versus the consensus estimate of $4.17 million.

Q1 2017 Highlights:

• Revenue for Q1 2017 of $4.3 million was up 89% from $2.3 million in Q1 2016. Quell contributed $3.1M revenue and DPNCheck contributed $0.8M revenue.
• Quell Q1 2017 shipments totaled 18,697 devices and 25,437 electrode reorder packages with a total invoiced value of $4.11 million. This was an increase from 14,301 devices and 19,993 electrode reorder packages with a total invoiced value of $3.46 million in Q4 2016.
• Quell retail availability expanded to nearly 3,000 stores. Quell is now available in selected stores of Target, CVS, Walgreens, Best Buy, Bed Bath & Beyond and Sam’s Club.
• Second generation Quell device was unveiled at CES 2017 and started shipping during the quarter.
• DPNCheck Q1 2017 revenue of $0.8 million was a new quarterly high. Shipments included 50,850 biosensors, up 45% from 35,025 biosensors in Q1 2016.
• The Company closed a private equity offering of $7 million.

For earnings history and earnings-related data on NeuroMetrix (NURO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance